Therapeutic Potential of Targeting Wnt/β-Catenin Pathway in Treatment of Colorectal Cancer: Rational and Progress

Afsane Bahrami; Forouzan Amerizadeh; Soodabeh ShahidSales; Majid Khazaei; Majid Ghayour-Mobarhan; Hamid Reza Sadeghnia; Mina Maftouh; Seyed Mahdi Hassanian; Amir Avan

doi:10.1002/jcb.25903

Therapeutic Potential of Targeting Wnt/β-Catenin Pathway in Treatment of Colorectal Cancer: Rational and Progress

J Cell Biochem. 2017 Aug;118(8):1979-1983. doi: 10.1002/jcb.25903. Epub 2017 Apr 25.

Authors

Affiliations

¹ Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
² Cancer Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
³ Department of Physiology, Neurogenic Inflammatory Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
⁴ Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
⁵ Department of Medical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

PMID: 28109136
DOI: 10.1002/jcb.25903

Abstract

Wnt/β-catenin pathway is one of the main/frequent dysregulated pathways in several tumor types, including colon cancer. Aberrant activation of this pathway is associated with cell proliferation, invasive behaviors, and cell resistance, suggesting its potential value as a therapeutic target in treatment of CRC. Several agents have been developed for targeting of this pathway (e.g, natural agents: curcumin, 3,3-diindolylmethane, phytoestrogen; Synthetic/small Wnt inhibitors: Rofecoxib; PRI-724, CWP232291; and monoclonal antibody against frizzled receptors, Vanituctumab). This review summarizes the current knowledge about the therapeutic potential of targeting Wnt pathway with particular emphasis on preclinical/clinical studies in treatment of colorectal cancer. J. Cell. Biochem. 118: 1979-1983, 2017. © 2017 Wiley Periodicals, Inc.

Keywords: COLON CANCER; INHIBITOR; THERAPEUTIC TARGET; Wnt/β-CATENIN.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antineoplastic Agents / therapeutic use*
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
Cell Proliferation / drug effects
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / genetics
Colorectal Neoplasms / metabolism
Colorectal Neoplasms / pathology
Curcumin / therapeutic use
Gene Expression Regulation, Neoplastic*
Humans
Indoles / therapeutic use
Lactones / therapeutic use
Molecular Targeted Therapy*
Pyrimidinones / therapeutic use
Signal Transduction
Sulfones / therapeutic use
Wnt Proteins / antagonists & inhibitors*
Wnt Proteins / genetics
Wnt Proteins / metabolism
beta Catenin / antagonists & inhibitors*
beta Catenin / genetics
beta Catenin / metabolism

Substances

Antineoplastic Agents
Bridged Bicyclo Compounds, Heterocyclic
ICG 001
Indoles
Lactones
Pyrimidinones
Sulfones
Wnt Proteins
beta Catenin
rofecoxib
Curcumin
3,3'-diindolylmethane